---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-036306"
form_type: "8-K"
ticker: "OKUR"
cik: "0001637715"
company_name: "OnKure Therapeutics, Inc."
filed_at: "2025-03-10T23:59:59+00:00"
generated_at: "2026-05-25T01:34:37.945947+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# OnKure Q4 2024 net loss $17.4M; cash $110.8M; PIKture-01 data in H2 2025

## Summary
- Net loss Q4 2024 $17.4M ($1.37/share) vs $9.5M ($30.14/share) in Q4 2023; R&D expense rose $5.6M.
- Cash and equivalents $110.8M; expected to fund operations into Q4 2026 through multiple clinical readouts.
- PIKture-01 Part A monotherapy enrollment near complete; PK and preliminary efficacy data expected H2 2025.
- Part B fulvestrant combination dosing initiated through 900 mg BID cohort; initial data due H2 2025.
- Pan-mutant PI3Kα development candidate to be announced in Q2 2025; aims for ~10x selectivity over wild type.

## SEC filing metadata
- accession: 0000950170-25-036306
- form_type: 8-K
- ticker: OKUR
- cik: 0001637715
- company_name: OnKure Therapeutics, Inc.
- filed_at: 2025-03-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1637715/000095017025036306/0000950170-25-036306-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1637715/000095017025036306/okur-20250310.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-036306
- JSON: https://secwatch.observer/filing/0000950170-25-036306.json
- Plain text: https://secwatch.observer/filing/0000950170-25-036306.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.